Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States
Menée aux Etats-Unis à partir des données 2010, 2013 et 2015 d'une enquête nationale de santé portant sur 19 690 patients âgés de 50 ans ou plus, cette étude analyse l'évolution de l'utilisation des tests de détection du PSA après la publication en 2008 et 2012 des recommandations de l'"US Preventive Services Task Force" en matière de dépistage du cancer de la prostate
Recommendations for prostate-specific antigen (PSA)-based prostate cancer screening have changed considerably in recent years. In 2008, the US Preventive Services Task Force (USPSTF) recommended against PSA-based prostate cancer screening among men 75 years or older, and in 2012, they recommended against PSA testing for men of all ages.1 Other organizations emphasize shared-decision making for men 50 years or older with a long life expectancy.2 As a result of shifting recommendations, PSA screening rates declined from 37.8% in 2010 to 30.8% in 2013 among men 50 years or older, resulting in substantial declines in prostate cancer incidence.3 However, it is not known if PSA testing has continued to decline. The objective of the present study was to examine PSA testing patterns using recently released 2015 National Health Interview Survey (NHIS) data.
JAMA Internal Medicine , résumé, 2016